UBS Group
INBX

UBS Group’s Inhibrx, Inc. Common Stock INBX Stock Holding History

UBS Group’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-445,197
Closed -$15.6M – 10500
2024
Q1 		$15.6M Buy
445,197
+364,412
+451% +$13.3M ﹤0.01% 1893
2023
Q4 		$3.07M Buy
80,785
+42,782
+113% +$917K ﹤0.01% 3333
2023
Q3 		$697K Buy
38,003
+36,192
+1,998% +$757K ﹤0.01% 4392
2023
Q2 		$47K Sell
1,811
-47,171
-96% -$1.1M ﹤0.01% 6508
2023
Q1 		$924K Sell
48,982
-40,265
-45% -$936K ﹤0.01% 4179
2022
Q4 		$2.2M Buy
89,247
+71,452
+402% +$2.1M ﹤0.01% 3306
2022
Q3 		$319K Buy
+17,795
New +$321K ﹤0.01% 4725
2022
Q2 		– Sell
-32,343
Closed -$721K – 11813
2022
Q1 		$721K Sell
32,343
-4,615
-12% -$118K ﹤0.01% 4413
2021
Q4 		$1.61M Buy
+36,958
New +$1.48M ﹤0.01% 3933
2021
Q2 		– Sell
-2,522
Closed -$51K – 10451
2021
Q1 		$51K Buy
2,522
+596
+31% +$17.4K ﹤0.01% 6542
2020
Q4 		$64K Buy
1,926
+839
+77% +$22.3K ﹤0.01% 5977
2020
Q3 		$20K Buy
+1,087
New +$19.7K ﹤0.01% 6335

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group's INBX Position: Q2 2024 in Review

UBS Group sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 445,197 shares — an estimated $15.6M sold.

UBS Group first reported a position in INBX in Q3 2020 and held it in 12 quarters. The position peaked at $15.6M in Q1 2024. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • UBS Group reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • UBS Group sold 445,197 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $15.6M.
  • UBS Group first reported a position in Inhibrx, Inc. Common Stock in Q3 2020 and held it in 12 quarters.
  • UBS Group's Inhibrx, Inc. Common Stock position peaked at $15.6M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.